C-Reactive Protein, Metabolic Syndrome and Cardiovascular Disease

Gen-Min Lin*, Yi-Hwei Li, Lamin E S Jaiteh and Chih-Lu Han

1 Department of Medicine, Hualien Armed Forces General Hospital, Hualien, Taiwan
2 Department of Public Health, Tzu-Chi University, Hualien, Taiwan
3 Department of Medicine, Royal Victoria Teaching Hospital, Banjalul - The Gambia
4 Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Editorial comment

C-reactive protein (CRP) has been known to be highly associated with the occurrence of cardiovascular disease. However controversies were present among some clinical trials with regard to the role of CRP to be the cause or a bystander in cardiovascular disease [1-3]. Experimentally, CRP was found to cause vascular endothelial dysfunction, increase matrix metalloproteinase synthesis and impair fibrinolytic capacity, which involve the process of atherosclerosis resulting in an increased cardiovascular risk [4,5]. On the contrary, CRP could be produced from the inflamed adipocytes in pericardial and abdominal visceral fat tissues and it did not correlate well to the severity of vascular atherosclerosis [6]. Furthermore, CRP was related to the development of metabolic syndrome as well and it has been interpreted to be the underlying mediator [7]. As we know, there was no additive or multiplier hazardous effect of CRP to some classic risk factors for cardiovascular diseases such as hypertension, coronary calcium score, hyperlipidemia and metabolic syndrome on the basis of subgroup analyses from the JUPITER trial, the ASCOT trial and the Framingham offspring study [8-12]. Recent genetic analyses demonstrated that carriers of CRP polymorphisms with higher serum CRP levels were not associated with higher cardiovascular risk [13]. Therefore, the controversies were still unresolved regarding the role of CRP in the pathogenesis of cardiovascular diseases.

Recently, we found CRP can reclassify Framingham intermediate cardiovascular risk patients with a family history of premature coronary heart disease without metabolic syndrome into high risk ones based on individual participant data. BMJ 342: d548.

References


Corresponding author: Gen-Min Lin MD, Department of Internal Medicine, Hualien Armed Forces General Hospital No.163, Jiali Rd., Xincheng Township, Hualien County 97144, Hualien, Taiwan. Tel: +863-3-826-0601; E-mail: farmer507@yahoo.com.tw

Received February 25, 2012; Accepted February 26, 2012; Published February 28, 2012


Copyright: © 2012 Lin GM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
